ID
17836
Description
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK A 24 week double-blind, randomized, placebo-controlled, parallel-group dose-raging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer´s disease. Medicine: rosiglitazone, Condition: Alzheimer´s Disease, Phase: 2, Clinical Study ID: AVA 100193, Sponsor: GSK. This ODM contains the Study Conclusion.
Keywords
Versions (2)
- 10/4/16 10/4/16 -
- 12/9/16 12/9/16 -
Uploaded on
October 4, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Study Conclusion
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Study Conclusion
- StudyEvent: ODM
Description
Pregnancy Information
Description
Status of Treatment Blind
Description
Was the treatment blind broken during the study?
Data type
text
Alias
- UMLS CUI [1]
- C2347038
Description
Date blind broken
Data type
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C2347038
Description
Reason
Data type
text
Description
Other
Data type
text
Description
Complete Non-Serious Adverse Event, Serious Adverse Event and/or Investigational Product pages, as appropriate
Data type
boolean
Description
Study conclusion
Description
Date of subject completion or withdrawal
Data type
date
Description
Was the subject withdrawn from the study?
Data type
boolean
Description
Reason for withdrawal
Data type
text
Description
Specification of Other
Data type
text
Description
Investigator´s signature
Similar models
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Study Conclusion
- StudyEvent: ODM
C2347038 (UMLS CUI [1,2])